A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 50
- Population
- ALL · 50 Years to 85 Years
- Duration
- 2026-08-31 to 2032-01-14
- Intervention
- JWK001; Aflibercept (2.0 mg)
- Comparator
- Aflibercept Active Comparator Group
- Outcomes measured
- Change from baseline in best-corrected visual acuity (BCVA) — Week 34; Change from baseline in BCVA — Week 50 and Year 5; Change from baseline in central retinal thickness (CRT) — Week 34, Week 50 and Year 5; Change from baseline in the area of Macular Neovascularization (MNV) — Week 34 and Week 50; Change from baseline in leakage area — Week 34 and Week 50; Annualized mean number of rescue treatments — Week 34, Week 50 and Year 5; Change from baseline in the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) score — Week 34 a…; Frequencies and severities of all safety events — Week 34 and Year 5
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.